Abstract
Neurofibrillary tau pathology (tangles and threads) and extracellular amyloid-β (Aβ) pathology are defining features of Alzheimer’s disease. For 25 years, most research has focused on the amyloid hypothesis of AD pathogenesis and progression. But, because of failures in clinical trials of Aβ-targeted therapies and the new concept of prion-like propagation of intracellular abnormal proteins, tau has come back into the spotlight as a candidate therapeutic target in AD. Tau pathologies are found in a range of neurodegenerative disorders, but extensive analyses of pathological tau in diseased brains has demonstrated that the abnormal tau protein in each disease is structurally distinct, supporting the idea that progression of the diverse but characteristic tau pathologies occurs through prion-like seed-dependent aggregation. Therefore, intervention in the conversion of normal tau to abnormal forms and in cell-to-cell transmission of tau may be the key to development of disease-modifying therapies for AD and other dementing disorders.
Cite
CITATION STYLE
Hasegawa, M. (2016, June 1). Molecular mechanisms in the pathogenesis of alzheimer’s disease and Tauopathies-Prion-Like seeded aggregation and phosphorylation. Biomolecules. MDPI AG. https://doi.org/10.3390/biom6020024
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.